Non-English-speaking families were far less likely to introduce peanut by 6 months (OR, 0.21) in a 3,170-child study presented at ACAAI 2026.
|Slideshows|June 21, 2019
FDA approvals you might have missed
Author(s)Miranda Hester
A look at 5 recent approvals from the US Food and Drug Administration (FDA), including treatment for systemic lupus erythematosus, a new gene therapy, and pain relief for patients with irritable bowel syndrome.
Advertisement
Advertisement
Related to this article
In an ACAAI 2026 survey, 85% of clinicians knew food allergy panels often yield false positives, yet many ordered them for unvalidated uses.
Full OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.
Classroom engagement scores in digital gradebooks predicted substance use by eighth grade better than GPA (cross-validated AUC, 0.79 vs 0.63).
Children living more than 60 miles from their surgical hospital had higher complication odds and longer stays after common procedures.
Emily Becker, MD, discusses the role of AhR agonists, skin barrier function, and steroid-free treatment options for pediatric atopic dermatitis.
Post hoc data show cariprazine improved both manic and depressive symptoms through 52 weeks in youth aged 10 to 17 years with bipolar I disorder.
CDC data show pediatric CP-CRE incidence rose 92% from 2019 to 2024, driven by NDM-CRE, mostly in children with complex medical needs.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
How pediatricians can reframe vaccine conversations
2
Risankizumab shows 52-week efficacy in pediatric psoriasis trial
3
FDA investigates malignancy risk with SMA gene therapy Zolgensma
4
Distance to surgery linked to complications, longer stays in children
5